A new report says that Pfizer India received necessary approval to launch Exubera.
According to Mint, India’s new business newspaper, Pfizer India’s Managing Director Kewal Handa reportedly discussed Pfizer’s diabetes drug push.
Marketwatch says that Mint estimates a diabetes drug growth-rate of 20-22% a year in the country.
Pfizer India will face competition from Eli Lilly & Co. (NYSE:LLY) and Merck KGaA (MRK.XE), two major diabetes drug companies expanding their efforts in the country.
Sphere: Related Content